Sinusitis, Acute Clinical Trial
Official title:
A Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, 2-week Treatment Study to Evaluate the Safety and Efficacy of Fluticasone Furoate Nasal Spray 110 mcg in the Treatment in the Treatment of Uncomplicated Acute Rhinosinusitis in Adults and Adolescents >= 12 Years of Age
The purpose of this study is to assess the safety and efficacy of fluticasone furoate nasal spray (FFNS), without the use of an antibiotic, in the treatment of adult and adolescent subjects who are 12 years of age and older with uncomplicated acute rhinosinusitis (ARS).
- Rationale - Acute rhinosinusitis (ARS) is a condition caused by inflammation of the nose
and the paranasal sinuses that generally lasts up to 4 weeks. Despite ARS being a
self-limiting condition, untreated or inadequately treated sinus infection can lead to the
development of complications. Uncomplicated ARS is a subset of ARS and is distinguished from
the common cold by the persistence or the worsening of sinus inflammation after the usual
period for recovery of viral infection of the nasal cavity (i.e., 10 days). Clinically the
difference is based on the following criteria: symptoms are present at least 10 days but
less than 4 weeks beyond the onset of upper respiratory symptoms OR symptoms worsen after 5
days from their onset.
In the primary care settings, ARS is often treated empirically with antibiotics although
they are shown to provide limited benefit in the uncomplicated ARS population.
Alternatively, the use of an intranasal corticosteroid (INS) to control symptoms of
uncomplicated ARS is plausible based on clinically proven ability to reduce inflammation and
mucosal swelling.
This study is a phase II study.
- Objective - The objective of this study is to evaluate the safety and efficacy of two
doses of FFNS (110 mcg once daily and 110 mcg twice daily) compared to placebo as
monotherapy in the treatment of adult and adolescent subjects 12 years of age and older
with uncomplicated ARS.
- Study Design - This is a randomized, double-blind, placebo controlled, parallel group,
multi-centre, 2-week treatment study. The study includes a 2-week post-treatment
follow-up period.
Approximately 720 subjects will be randomized to one of three treatment groups for a period
of 14 days: FFNS 110 mcg QD, FFNS 110 mcg BID, and placebo nasal spray.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03729258 -
Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis.
|
Phase 3 | |
Recruiting |
NCT04241016 -
Endoscopic Sinus Surgery in Recurrent Acute Rhinosinusitis
|
N/A | |
Recruiting |
NCT05924711 -
"Association of Peri-implantitis and Maxillary Sinusitis: a Case-control Study".
|
||
Terminated |
NCT03431337 -
Treatment of Acute Sinusitis With High-Dose vs. Standard-Dose Amoxicillin/Clavulanate
|
Phase 4 | |
Completed |
NCT01934231 -
Study to Assess the Efficacy and Safety of Potassium Clavulanate/Amoxicillin in Children With Acute Bacterial Rhinosinusitis
|
Phase 3 |